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Background: Chronic hepatitis C virus (HCV) infection is a major worldwide public 
health problem. Egypt has the highest prevalence of adult HCV infection in the world, 
averaging 15%–25% in rural communities. Mannan-binding lectin (MBL) is a liver-derived 
pluripotent serum lectin that plays a role in the innate immune system of the host. It 
is an acute-phase protein that is involved in the activation of the classical complement 
pathway. MBL may play a defensive role in HCV infection.
Objectives: To investigate the relationship between MBL concentration and HCV infec-
tion in Egyptian patients suffering chronic hepatitis C.
Patients and Methods: Serum samples obtained from 35 Egyptian hepatitis C patients 
and 30 normal controls were assayed for MBL. MBL concentrations were correlated to 
disease characteristics and treatment response.
Results: Serum MBL was significantly higher in HCV patients than in controls, but no 
relationship was found between MBL concentration and disease progression in terms 
of hepatic fibrosis and inflammation. Responders to interferon (INF)-based therapy had 
significantly higher serum MBL than non-responders. 
Conclusions: We found no association between serum MBL concentration and progres-
sion of HCV related liver disease. Responders to INF-based therapy had significantly 
higher serum MBL than non-responders. 
  Please cite this paper as: 
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 Implication for health policy/practice/research/medical education:
MBL may be considered as a predictor of response to antiviral therapy in HCV patients and MBL replacement therapy may improve 
the response to antiviral therapy in these patients.
  c 2012 Kowsar Corp. All rights reserved.
1. Background
Mannan-binding lectin (MBL) is an acute-phase protein 
that is involved in the activation of the classical comple-
ment pathway (1). MBL acts as a direct opsonin by bind-
ing to collectin receptors through its collagen domain 
(2). Serum levels of MBL in humans are highly influenced 
by inherited haplotypes that differ at a series of allelic di-
morphisms. These differences can influence the structur-
al gene and its promoter region (3-5). Other factors can 
affect plasma MBL, including growth hormone (6). The 
MBL genotype of a person provides only a general idea of 
the expected plasma concentration and different combi-
nations of haplotypes are associated with a wide range of 
MBL concentrations (4, 5). Genotypes are good indicators 260 Hepat Mon. 2012;12(4)
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of the average MBL concentrations of populations; how-
ever, they provide a less reliable prediction of plasma 
MBL for individuals (4). Approximately 60–85% of those 
infected with HCV cannot eradicate the virus and prog-
ress to chronic hepatitis (7, 8). This high rate of viral chro-
nicity may be explained by a failure in the host immune 
response or by the ability of HCV to defeat host defense 
mechanisms (7, 8). MBL acts as a recognition molecule 
for pathogen-associated molecular patterns (PAMPs) 
which play a role in the initiation and regulation of the 
immune response (9). The role of MBL in HCV pathogene-
sis has received a lot of attention in the last few years (10). 
MBL activates the complement system, which results in 
destruction of pathogens by the membrane attack com-
plex or by complement-mediated phagocytosis. MBL can 
engage in phagocytosis of infecting agents to modulate 
the release of proinflammatory cytokines (10-12). Many 
previous studies of MBL and hepatitis C based diagno-
ses solely on serology, but included patients with differ-
ent clinical forms of HCV infection ranging from those 
with no liver involvement, to those with cirrhosis. This 
compromises the analyses of the severity of liver involve-
ment (13-17). Studying the results of liver biopsies is the 
gold standard for grading hepatitis C. MBL may play an 
immunomodulatory role during treatment with IFN, as 
MBL regulates the release of different cytokines from im-
mune cells in response to infection (18).
Hepatitis C-infected patients with MBL haplotypes that 
were known to confer low MBL concentrations are signif-
icantly less likely to respond to interferon (INF) therapy 
than similar patients who are genetically able to produce 
greater amounts of MBL (14). This may be important, be-
cause the expense, adverse side-effects, and long dura-
tion of antiviral therapy make screening for potential 
non-responders desirable (14). The clear implication that 
MBL plays a major role in elimination of the virus raises 
the possibility that MBL replacement therapy may be 
beneficial for hepatitis C carriers with low levels of MBL 
(14). However, at least one other study (19) found that sus-
ceptibility to hepatitis C infection is not increased by low 
circulating MBL, and MBL concentration does not play a 
big role in the course of the disease or patient response 
to antiviral therapy. If this is the case, MBL replacement 
therapy would not be beneficial for chronic hepatitis C 
patients who failed to respond fully to treatment with 
interferon and ribavirin (19).
2. Objectives
We therefore aimed to investigate the relationship be-
tween MBL concentration and hepatitis C infection at the 
protein level in Egyptian patients suffering from chronic 
hepatitis C.
3. Patients and Methods
3.1. Patients
Thirty-five randomly selected HCV patients that were 
candidates for IFN-based therapy and 30 healthy volun-
teers participated in the study. Patients were recruited 
from the outpatient clinics of the internal medicine and 
tropical medicine departments, Kasr Al Aini hospital, 
Cairo University. 
3.2. Methods
We collected serum samples from all patients and 
controls. Serum was tested for HCV antibodies and MBL 
concentration. Other laboratory tests included fast-
ing blood glucose, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase, 
serum creatinine, serum albumin and complete blood 
count. Samples were drawn after an overnight fast and 
were measured using standard commercial methods on 
a parallel multi-channel analyzer (Hitachi 7170A, Tokyo, 
Japan). All HCV patients were subjected to the following: 
1). quantitative polymerase chain reaction (PCR) assay for 
HCV before starting treatment and 12 weeks after begin-
ning treatment. Patients that responded to treatment 
were tested again 6 months after beginning and at the 
end   of treatment. 2) Liver biopsy as a routine measure 
before starting treatment. 3) Alpha-fetoprotein (AFP). 
PCR for HCV RNA was performed on samples from con-
trols as well as patients. All participants in the control 
group tested negative.
HCV RNA was extracted from a 200 μL serum sample us-
ing Ana-gen RNA extraction kit (Qiagene, USA) according 
to the manufacturer’s instructions. cDNA was prepared 
by Reverse transcription PCR using M-MLV reverse tran-
scriptase (Fermentas, USA). The amplified cDNA was fur-
ther subjected to 2 rounds of PCR amplifications using 
a highly conserved primer sequence, upstream primer 
5′-GCAGAAAGCGTCTAGCCATGGCGT and downstream 
primer, 5′-CTCGCAAGCACCCTATCAGGCAGT. The condi-
tions for the first round of PCR were as follows: an initial 
denaturation step at 95°C for 2 min followed by 30 cycles 
of 45 s at 94°C, 45 s at 54°C, and 1 min at 72°C. PCR cycling 
conditions for the second round are as for first round am-
plification except for an annealing temperature of 54°C.
All PCR products (first and second rounds) were analyzed 
on 1.8% agarose gel prepared in 0.5% TBE buffer, stained 
with ethedium bromide and visualized by ultraviolet 
(20). Ultrasound-guided biopsy was performed for all 
patients using 18–20 gauge needles (, GHATWARY MEDI-
CAL SUPPLIES, Alexandria, Egypt). Diagnostic liver biopsy 
specimens were scored using the Ishak modified histo-
logical activity index (HAI) and Ishak fibrosis stages (21). 
Before treatment, MBL was measured in serum samples 
using an enzyme-linked immunosorbent assay (ELISA) 
kit (Hycult Biotech, Uden, Netherlands). Briefly, a stan-
dard curve was prepared by serial dilution of standards 
supplied with the assay. Standards and serum samples 
were added to a 96-well plate containing immobilized 
antibodies specific to MBL. The plate was incubated at 
room temperature for 2 h, with gentle shaking. Follow-
ing extensive washing, bound MBL was detected using 261 Hepat Mon. 2012;12(4)
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an HRP-conjugated polyclonal antibody against the tar-
get protein. The detection antibody was incubated for 2 
h at room temperature, and detected using 3,5,3′,5′-tet-
ramethylbenzidine (TMB) and 3% H2O2. The reaction was 
terminated by the addition of sulfuric acid provided with 
the kit. Optical density was detected using a microplate 
reader at 450 nm with a wavelength correction reading 
at 540 nm. Concentrations of unknowns were calculated 
from the standard curve (22).
 Patients were given a course of antiviral therapy con-
sisting of Peginterferon alfa-2a (Pegasys®) 180 mcg (re-
gardless of body weight) subcutaneously once weekly 
and 10.6 mg/kg ribavirin orally every day (combination 
therapy). After 12 weeks of treatment, patients with a re-
duction of more than 2 logs in PCR results were deemed 
to be responders and continued treatment for a total of 
48 weeks. Responders (n = 20) were tested again 6 months 
after the end of therapy using PCR to ensure sustained 
virological response (SVR). Patients with PCR scores that 
were not at least 2 logs lower after 12 weeks of therapy 
than at baseline were deemed to be non-responders (n 
= 11). Four patients were lost to follow-up during INF-
based therapy. Informed consent was obtained from all 
patients and controls.
3.3. Statistical Analysis 
All patient data were tabulated using Excel 7. Data were 
then processed using SPSS (Statistical Package for Science 
and Society) version 17.0 (SPSS Inc., Chicago, IL, USA) for 
Windows 7 (Microsoft, Corporation, NY, USA). Descrip-
tive statistics are presented as means ± standard devia-
tions (SD) for quantitative variables. All qualitative data 
are expressed as frequencies (number) and percentages. 
Groups were compared using chi-square test and Fisher’s 
test, as appropriate for qualitative data. Independent 
sample t-test was used for comparing normally distrib-
uted quantitative variables between groups and non-
parametric Mann–Whitney test and Kruskal–Wallis test 
were used to compare abnormally distributed quantita-
tive variables between groups. Correlation analysis was 
used when appropriate. P values lower than 0.05 were 
considered statistically significant for all tests.
4. Results
Our study included 35 patients between 19 and 56 years 
of age (20 males, 15 females, mean age: 37.43 ± 9.65). Base-
line characteristics of patients are summarized in Table 1. 
The control group included 30 healthy subjects between 
18 and 55 years of age (18 males, 12 females, mean age: 
36.8 ± 11.885). The characteristics of the control group 
are shown in Table 1. We performed multivariate analysis 
to adjust for age and gender effects, but neither age nor 
gender significantly affected other variables (P ˃ 0.05). 
MBL concentrations were significantly higher in chronic 
hepatitis C patients (P ˂ 0.001) than in controls (1330.47 
± 497.81  ng/mL in patients vs. 619 ± 136 ng/mL in the con-
trols; Figure 1). There was a significant positive correla-
tion between serum MBL level and alpha-fetoprotein in 
the HCV infected group (Figure 2). Within the HCV group, 
the fibrosis scores were 1, 2, and 3 in 16, 12, and 7 patients, 
respectively. The activity score for inflammation was 
1, 2, and 3 in 10, 7, and 18 patients, respectively (Table 2). 
MBL concentrations did not differ significantly between 
different  grades  of  liver  fibrosis  and  liver  inflamma-
                                Patients                             Control Group
Minimum Maximum mean ± SD Minimum Maximum mean ± SD
Age, y 19 56 37.43 ± 9.65 18 55 36.80 ± 11.89
Body weight, Kg 53 105 79.79 ± 14.61 66 107 89.43 ± 10.85
Blood glucose, mg/dL 60 321 103.50 ± 43.38 68 112 87.60 ± 12.36
Creatinine, mg/dL 0.44 1.30 0.82 ± 0.20 0.4 1.1 0.74 ± 0.18
AlP a, IU/L 6.20 252.00 79.09 ± 41.45 56 129 81.53 ± 20.53
AST a, IU/L 10 283 54.50 ± 49.76 13 30 18.93 ± 5.66
ALT a, IU/L 8 243 62.51 ± 46.18 12 30 17.43 ± 5.28
T. Bilirubin a, mg/dL 0.24 1.80 0.83 ± 0.34 0.22 1 0.52 ± 0.21
Albumin, gm/dL 3.2 5.10 4.68 ± 0.99 3.9 4.9 4.41 ± 0.30
Hb a, gm/dL 11.0 16.9 14.11 ± 1.54 10.9 14.8 12.65 ± 0.82
Platelet/cmm 110,000 347000 203471 ± 58514 222.000 390000 296533.30 ± 48131.09
WBCs a /cmm 3100 11720 6775.14 ± 1895.65 4200 9000 6017.66 ± 1421.04
AFP a, ng/mL 1.6 44.1 5.29 ± 8.19 -- -- --
MBL a, ng/mL 146.3 2163.0 1330.47 ± 497.81 502 916 619 ± 136
Table 1. Baseline Characteristics of HCV Patients and Healthy Controls
a Abbreviations: AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; 
MBL, mannan binding lectin; T Bilirubin, total bilirubin; WBC, white blood cell262 Hepat Mon. 2012;12(4)
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tion (Table 2). Twenty patients showed SVR to INF-based 
therapy, while 11 patients were non-responders. Serum 
MBL was significantly higher in responders than in non-
responders (Table 3).
5. Discussion
Egypt has the highest prevalence of adult HCV infection 
in the world, as 15%–25% of the population in rural com-
munities is infected (23, 24). The outcome of HCV infec-
tions are usually associated with the interaction between 
the virus and the host immune response (25). Mannan-
Frequency, No. MBL a, ng/mL, mean ± SD P value
Fibrosis score 35 0.79 b
1
2
3
16
12
7
1285.46 ± 438.42
1317.02 ± 540.5
1447.9 ± 513.6
Activity score 35 0.52 b
1
2
3
10
17
8
1259.82 ± 622.11
1337.5 ± 458.5
1471.3 ± 480.8
a Abbreviation: MBL, Manran Binding Lection
b Kruskal–Wallis test was performed to obtain the P value
Table 2. Serum MBL in Different Grades of Liver Fibrosis and Hepatic Inflammation in the Patients Infected With HCV
Patient Groups (n = 35) No. MBL, ng/mL
Non responders b 11 1023.78 ± 163.11
Responders c 20 1882.36 ± 291.34
Missed d 4 1879.87 ± 237.25
Table 3. Serum MBL Among Responders and Non-Responders to INF-
Based Therapy a
a P ˂ 0.001; Kruskal–Wallis test was performed to obtain the P value
b Less than 2 logs reduction in PCR after 12 weeks of therapy
c More than 2 logs reduction in PCR after 12 weeks of therapy and nega-
tive PCR at week 72 (SVR)
d More than 2 logs reduction in the PCR after 12 weeks of therapy, but 
dropped out of study before completion of the 48-week course of therapy
Figure 1. Mean Serum MBL Concentration Was Significantly Higher in 
Chronic Hepatitis C Patients Than in Controls (P < 0.001; Mann–Whitney 
Test).
Figure 2. Correlation Between Serum MBL Level and Alpha-Fetoprotein 
(AFP) in the HCV Infected Group (R = 0.59, P < 0.001; Spearman Correla-
tion Test).
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binding lectin (MBL) is a liver-derived pluripotent se-
rum lectin that plays a role in the host immune system 
(12). The current study investigated the serum MBL level 
among Egyptian patients with chronic hepatitis C. We 
found that chronic HCV patients had higher MBL con-
centrations than healthy controls. This can be explained 
by the fact that MBL is an acute phase reactant (26). How-
ever, our results contradict those of Yuen M-F et al. 1999 
(27) who reported that asymptomatic HCV patients had 
lower MBL levels than controls. While not statistically 
significant, MBL concentration tended to increase with 
the grades of fibrosis and hepatic inflammation. Other 
authors have also observed a statistically non-significant 
link between high serum MBL and more severe fibrosis 
(28). Further studies with larger numbers of patients are 
needed to assess this relationship. Although the associa-
tion between the concentration of MBL and hepatitis se-
verity was not statistically significant, it may still be real, 
and may reflect MBL’s role as an acute phase reactant. 
This is consistent with the highly significant increase in 
MBL in hepatitis C patients as compared to normal con-
trols that we observed.
Serial AFP measurements in patients with chronic 263 Hepat Mon. 2012;12(4)
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hepatitis C are useful for identifying persons with ad-
vanced fibrosis and help to determine which patients 
need periodic liver ultrasound screening to detect HCC 
(29). In our study, a significant positive correlation was 
found between serum MBL and AFP level. Moreover, both 
increased as the fibrosis stage became more advanced. 
This finding supports the hypothesis that MBL may be 
related to disease progression. In the current study, non-
responders to INF-based therapy had significantly lower 
MBL concentration than responders. However, both had 
significantly higher MBL levels than normal controls. The 
lower levels of MBL in non-responders may be explained 
by the inhibitory effect of HCV on MBL production from 
the liver (13). Those with higher levels of MBL may have a 
better ability to eliminate the virus (14). MBL may play an 
immunomodulatory role during treatment with IFN, as 
MBL regulates the release of various cytokines from im-
mune cells in response to infection (18).
 Progression of chronic hepatitis B and C are reported to 
be associated with MBL insufficiency (13-15, 30). Thio et al. 
(31) reported that recovery from hepatitis B infection was 
associated with high MBL serum levels while persistence 
of the virus was associated with low MBL serum levels. 
Liver cirrhosis has also been linked to low serum levels 
of MBL (27). Additionally, spontaneous bacterial perito-
nitis (SBP) is much more common in MBL-deficient cir-
rhotics (27). SBP is a serious disease and prevention of SBP 
in MBL-deficient cirrhotics with MBL therapy would be a 
valuable advance. This disease is a good candidate for 
a clinical trial of MBL therapy. Responders to INF-based 
therapy had significantly higher serum MBL than non-
responders. MBL may be a predictor of antiviral therapy 
response in HCV patients. Further studies are needed to 
evaluate MBL replacement therapy, which may improve 
the response to antiviral therapy in these patients. The 
possible relationship between serum MBL concentration 
and progression of HCV-related liver disease deserves 
further evaluation with a larger number of patients.
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